IL13Rα2 CAR-T cell therapy(TCRCure Biopharma)

N/A

Report date: 2026/01/21 20:00:47

Base Information

Drug NameIL13Rα2 CAR-T cell therapy(TCRCure Biopharma)
Drug Alias NameIL-13Rα2 Targeted Chimeric Antigen Receptor T Cell therapy(TCRCure Biopharma)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsInterleukin-13 receptor subunit alpha-2 modulators
TargetsInterleukin-13 receptor subunit alpha-2
Therapy Area/IndicationsGlioma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesTcrcure Biopharma Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTcrcure Biopharma Ltd
Active IndicationsN/A
Inactive IndicationsGlioma

Other Information

ATC CodeN/A
Related LinksN/A